TORONTO, May 01, 2019 (GLOBE NEWSWIRE) -- WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report its financial results for the fourth quarter and fiscal year ending December 31, 2018.
WeedMD reports revenues of $8.2M in its second year of operations representing a year-over-year increase of 465%. Revenues were driven by a combination of increased cannabis sales to medical patients, supply agreements for Canada’s adult-use market in addition to the sale of wholesale cannabis and genetics to other licensed producers. The Company is well financed with a strong cash balance of $21.2M as of December 31, 2018.
|For the years ended December 31||2018||2017|
|Net and Comprehensive Loss||(895,128)||(8,805,222)|
|Adjusted Operating Loss*||(11,737,061)||(7,042,047)|
|Cash Used from Operations||(615,514)||(2,986,928)|
|Earnings (Loss) per Share (Basic and Fully Diluted)||(0.01)||(0.15)|
|As at||December 31, 2018||December 31, 2017|
|Cash and Cash Equivalents||21,223,641||24,695,152|
|*Adjusted Operating Loss is not a recognized measurement under IFRS and this data may not be comparable to data presented by other companies. Management believes Adjusted Operating Loss to be an important measure of the Company’s day-to-day operations, by excluding non-cash gains and losses and/or non-recurring items.|
Corporate Highlights Fiscal Year 2018
Sales, Marketing & Business Development Milestones
Key Leadership Appointments
Greenhouse Construction Timetable
The ramp up of the Strathroy facility continues on schedule as follows:
Strathroy Cultivation Expansion & 2019 Harvest Schedule
|Expected Construction |
|Licence Issue Date |
Space (Sq Ft)
|Measurement||# of Rooms||Licences|
|Phase 1||Hybrid GH||Complete||June 2018||44,000||Sq Ft||4||Cultivation, Sale|
|Phase 2||Hybrid GH||Complete||December 2018||66,000||Sq Ft||6||Cultivation, Sale|
|Phase 3||Hybrid GH||March 2019||June 2019 (expected)||110,000||Sq Ft||10||Amendment submitted|
|Phase 4||Standard GH||June 2019||Q3 2019 (expected)||308,000||Sq Ft||2||Amendment to existing licence|
|Outdoor||Expected Construction |
|Licence Issue Date |
Space (Sq Ft)
|Phase 1||Outdoor||May 2019||June 2019 (expected)||1,100,000||27||1||Amendment to existing licence|
|Phase 2||Outdoor||Q2 2020||Q2 2020 (expected)||3,200,000||73||3||Amendment to existing licence|
“Our team achieved a number of key milestones in 2018 as we rapidly built out and licensed our industry-leading production platform in record time to address the onset of the adult-use market. We signed key supply agreements with six provinces and added Shoppers Drug Mart to our distribution network. With our focus on operational excellence, we added key members to round out a formidable leadership team,” said Keith Merker, CEO of WeedMD. “Our solid base of operations and rapidly expanding production platforms sets the pace for completing our build out this year. With our greenhouse and outdoor platforms, WeedMD is well-positioned for very significant organic growth in 2019. We look forward to taking WeedMD to the next level with the launch of new brands, the roll out of new products, the build out of an international presence in addition to expanding our extraction and processing operations whilst exploring M&A opportunities to drive shareholder value.”
The Company’s financial statements and related management’s discussion and analysis for the period are available under the Company’s profile on SEDAR at www.sedar.com. All amounts are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards unless otherwise noted.
About WeedMD Inc.
WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of cannabis products for both the medical and adult-use markets. The Company owns and operates two facilities: a 26,000 sq. ft. indoor facility in Aylmer, Ontario and a 158-acre state-of-the-art greenhouse and outdoor facility located in Strathroy, Ontario. The Company currently has 136,000 square feet of licensed production space across its facilities and is expected to have a total footprint of more than 550,000 square feet of indoor and greenhouse production in addition to more than 25 acres of outdoor cultivation space online in the first half of 2019. WeedMD has a multi-channeled distribution strategy that includes selling directly to medical patients, strategic relationships across the seniors’ market and supply agreements with Shoppers Drug Mart as well as six provincial distribution agencies.
Follow WeedMD On:
For further information, please contact:
Keith Merker, Chief Executive Officer
Tel: 519-765-2440 Ext. 201
To learn more, visit us at www.weedmd.com
For Media Inquiries:
VP, Communications & Corporate Affairs
Cautionary Statement on Forward-Looking Information
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon WeedMD's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy.
The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information in this news release include, but are not limited to, statements with respect to internal expectations, expectations with respect to actual production volumes, expectations for future growing capacity and the completion of any capital project or expansions. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally; the ability of WeedMD to implement its business strategies; competition; crop failure; and other risks.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, WeedMD does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for WeedMD to predict all such factors. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in WeedMD's Annual Information Form dated December 13, 2017 (the "AIF") and other disclosure documents of WeedMD filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the AIF and other disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE